Society of Urologic Oncology (SUO) Annual Meeting Wednesday, November 29, 2017 1:30 p.m. ET | Description | Seth Lerner, M.D., principal investigator for the Company’s ongoing pivotal Phase 3 OLYMPUS trial of MitoGel™ for the treatment of low-grade upper tract urothelial carcinoma (UTUC), will conduct an oral presentation during a plenary session at the 18th annual meeting of the Society of Urologic Oncology (SUO), taking place November 29-December 1, 2017, in Washington, D.C.
Dr. Lerner will provide an overview of the design of the Phase 3 OLYMPUS trial, including metrics of success and basic patient inclusion and exclusion criteria. In addition, Dr. Lerner will present key data highlights from the Company’s recently completed compassionate use program with MitoGel™ for the treatment of UTUC. Topline data from the Phase 3 OLYMPUS trial are expected to be available in the second quarter of 2018.
Details of the presentation are as follows:
Title: Thermo Reversible Hydrogel Based Delivery of Mitomycin C (MitoGel) for Treatment of Upper Tract Urothelial Carcinoma
Presenter: Seth Paul Lerner, M.D., FACS, Professor of Urology at Baylor College of Medicine
Time: Thursday, November 30, 2017, 1:30 p.m. EST
Location: Renaissance Washington DC Downtown Hotel, Washington, D.C.
|
|
|